Back to Search Start Over

Edo-S101, a Bendamustine (BDM)/ Histone-Deacetylase Inhibitor (HDACi) Fusion Molecule, Demonstrates Potent Preclinical Activity Against T-Cell Malignancies and Overcomes BDM-Resistance

Authors :
De Filippi, Rosaria
Crisci, Stefania
Mele, Sara
Zanotta, Serena
Corazzelli, Gaetano
Galati, Domenico
Coppola, Davide
Maiolino, Piera
Saggese, Mariangela
Volzone, Francesco
Morelli, Emanuela
Donnarumma, Daniela
Marcacci, Gianpaolo
Frigeri, Ferdinando
Odum, Niels
Mehrling, Thomas
Pinto, Antonio
Source :
Blood; December 2017, Vol. 130 Issue: 1, Number 1 Supplement 1 p2547-2547, 1p
Publication Year :
2017

Abstract

Introduction:T-cell and natural killer (NK)-cell lymphomas encompass a heterogeneous spectrum of malignancies with variable degrees of biological and clinical aggressiveness and different patterns of nodal/extra nodal dissemination. Despite advances in understanding of their genetic landscape, treatment options for these tumors are limited and survival remains dismal especially in patients (pts.) who relapse/progress after frontline treatment. Therefore, development of new active agents is a pressing medical need in this setting. The unconventional alkylator BDM and HDACi are clinically effective in pts. with recurring disease and the combination of these agents was suggested as a way to overcome early resistance and improve response and survival rates in T-cell tumors. Since EDO-S101 is a fusion molecule that combines the active structures of BDM and the pan-HDACi vorinostat to simultaneously damage DNA and block damage repair, we investigated its antitumor activity in preclinical models of human T- and NK- lymphomas.

Details

Language :
English
ISSN :
00064971 and 15280020
Volume :
130
Issue :
1, Number 1 Supplement 1
Database :
Supplemental Index
Journal :
Blood
Publication Type :
Periodical
Accession number :
ejs56856099
Full Text :
https://doi.org/10.1182/blood.V130.Suppl_1.2547.2547